Acute pancreatitis is a serious disease with a high mortality. The application of general medical and surgical measures such as intestinal decompression and the correction of dehydration and electrolyte imbalance has reduced this mortality significantly, but more specific therapeutic measures are needed. The most widely accepted theory for the causation of acute pancreatitis at the present time is the activation of pancreatic trypsinogen with digestion of the pancreas (Forell, 1962) , and the subsequent activation of potent circulatory enzymes, kallikrein and bradykinin, which may account for the severe clinical states found (Thal et al., 1963 ; Forell, 1963) . If this theory is correct the possession of a potent non-toxic trypsin and kallikrein inhibitor should assist greatly in the management of this disease. Such an inhibitor was isolated from the parotid gland of cattle by Frey et al. (1950) , and is now marketed as Trasylol, a polypeptide of low molecular weight capable of intravenous or intraperitoneal administration with few sideeffects. This drug has potent antitryptic activity in vitro (Moshal et al., 1963) , and has been shown to be capable of preventing the development of experimentally induced pancreatitis in animals (McHardy et al., 1963 ; McCutcheon, 1963 McCutcheon, , 1964 . However, despite widespread use in acute pancreatitis in humans it is still not possible to determine its value in the treatment of this disease, as most reports have been of uncontrolled clinical observations (Maurer, 1961 ; Forell, 1963 McHardy et al., 1963 Moshal et al., 1963) .
The only report of a double-blind study is a sentence in a review by Nardi (1963) that he found the drug of no benefit in such a trial, but that his figures were too small for statistical analysis.
The purpose of this paper is to report a double-blind study of the use of this drug in acute pancreatitis of all degrees of severity treated in other respects by the usual therapeutic measures.
Materials and Methods
All patients admitted to Royal Prince Alfred Hospital with a provisional diagnosis of acute pancreatitis were included in the trial. The diagnosis was confirmed by elevated serum amylase levels (>600 Somogyi units/100 ml.), plain x-ray film of the abdomen (to exclude gastro-intestinal rupture), and in two cases by laparotomy.
Patients with acute pancreatitis were allotted in random order to treatment with either Trasylol or a placebo (normal saline). All ampoules were identical in every respect, so that the identity of the administered substance was unknown to all persons connected with the trial until after its conclusion.
All patients were treated with intravenous therapy and intragastric suction, as well as general supportive and replacement therapy such as intravenous albumin, calcium, antibiotics, and anticholinergics. In every case an initial loading dose of the " drug" was given intravenously and followed by continuous intravenous infusion over a number of days. As the trial progressed the amount given was increased, as overseas experience suggested that higher doses could be more beneficial. Some of the small doses (see Table II The overall results of the trial (Table I ) clearly show that the Trasylol group fared worse than the controls. Table II shows the results when the patients are classified according to severity of disease. Unfortunately, the patients fell unevenly into the two treatment groups, but in all grades of severity the placebo-treated fared equally as well as the Trasylol-treated, and indeed may be regarded as having done better, for in no instance was an A response gained by Trasylol. Table III shows the results when types 1 and 2 are combined.
To determine whether delay in starting treatment could have contributed to the results we compare response with such delay (Table IV) mild, moderate, or severe, young or old, early or late treatment -and no matter how the cases are divided the same result appears. The failure to gain a single A result, manifest by response to the initial dose, clinical improvement in 24 hours, and ability to discontinue intravenous therapy in 48 hours, in the Trasylol group is particularly disturbing, for even in the mild-to-moderate group Trasylol failed to achieve an A result
In considering these results it should be noted that Trasylol itself appears to be non-toxic. The LD50 for mice, according to the manufacturer, is 2.5 million kallikrein inhibitor units/ kg., given intravenously. Very large doses (in excess of one million units at a time) have been given to humans without toxic reactions. One of our patients with recurrent pancreatitis developed hypotension and chest pain an hour after an intravenous dose of Trasylol. This may have been a delayed reaction to that drug, but other causes for the pain were not adequately excluded. This patient was again given Trasylol without severe reaction. It might be claimed that delay in starting treatment may have influenced the results in this trial, for the antitryptic effect of -Trasylol would be expected to be of particular benefit in the early stages of the disease before major pancreatic damage had -occurred. This hypothesis finds no support in this study 0o,ooo (Table IV) , for the Trasylol-treated cases on the whole were !5,000 treated earlier than those on the placebo, and of the three cases >0000 treated with Trasylol under 12 hours (only one was over 60)
,00
two were in the mild-to-moderate group, and one in the moderate-to-severe group, but still a B result was the best that could be achieved. Trasvlol-treated patients in the over-60 years and acute haemorrhagic pancreatitis (type 1' groups might explain this picture, but it must be said that Trasvlol failed to benefit any groupIt is of interest that a number of the medical officers concerned with treating patients in this trial felt certain they knew whether Trasylol or placebo was being administered in a number of instances because of a dramatic improvement in the patient after the beginning of treatment. In almost every case their judgment was incorrect, and a dramatic response was more often due to the placebo than to Trasylol. In fact, one of the most heartening aspects of this trial was the good response which could be obtained by intensive intravenous therapy with saline, albumin, calcium, and antibiotics combined with intragastric suction. In this trial there were many examples of dramatic relief of pain after the first injection at the " drug " and very rapid clinical improvement over the following 24 to 48 hours. When the results were analysed then events were found to occur with equal frequency in Trasylol and placebo-treated cases, so that one gains the strong impression that an enthusiastic clinical team giving their patients close attention and vigorous therapy will obtain improved results. It follows that a double-blind study is the only way in which a valid assessment of a drug such as Trasylol can be achieved.
The complete failure of Trasylol to obtain anything approaching the remarkable results obtained in experiments pancreatitis must cast grave doubts on the relevance to human pancreatitis of the experimental models used.
Further, the report by Beck et al. (1964) of failure to recover trypsin from areas of trypsin-induced pancreatitis after 20 minutes must discredit trypsin as a major perpetuating factor in pancreatitis. In this context a trypsin inhibitor such a Trasvlol would not be expected to exert any effect. Again, whether this type of pancreatitis has any similarity to human pancreatitis is open to question.
Summary
The effect of Trasylol (an antitryptic agent) in the treatment of acute pancreatitis of all grades of severity has been assessed in a double-blind studs-. Twenty-three episodes of pancreatiti were treated, 11 with Trasvlol and 12 with the placebo (norms! saline,. classified according to their response to the initial dose of the " drug," their general clinical improvement, the duration of intravenous therapy and intragastric suction, and the frequency of complications. Overall results of the trial show that the Trasvlol-treated patients did no better than the controls, and indeed may have fared worse. Although more Trasylol-treated patients had severe pancreatitis there was no difference in outcome at any grade of severity. The poor results with Trasylol could not be attributed to delay in starting therapy or to the age of the patient.
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